Novan, Inc. (NASDAQ:NOVN) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Separation and Consulting Agreements with Jeff N. Hunter

As previously disclosed, Jeff N. Hunter, Executive Vice President and Chief Business Officer, notified Novan, Inc. (the “Company”) of his resignation from the Company, including from serving as the Company’s principal financial officer and Secretary. On January 29, 2019, the Company and Mr. Hunter entered into a Separation and General Release Agreement (the “Separation Agreement”) and Consulting Agreement (the “Consulting Agreement”).

The Separation Agreement provides that Mr. Hunter will resign from all of his positions with the Company effective January 31, 2019 (the “Separation Date”) and, contingent upon execution of a general release agreement and ongoing compliance with the terms of the Separation Agreement and his existing confidentiality and noncompetition agreements with the Company, as modified therein, will receive severance in the aggregate amount of $350,000 to be paid in installments over 12months following the Separation Date in accordance with standard payroll practices, a lump sum payment equal to $61,250, and reimbursement for the cost of continuing COBRA coverage for a period of 12 months following the Separation Date or until Mr. Hunter is eligible for new group healthcare coverage, if earlier.

The Consulting Agreement provides that Mr. Hunter will provide supporting consulting services related to two ongoing corporate development projects at the Company from the Separation Date through September 30, 2019, and as compensation, Mr. Hunter will receive up to $61,250 payable upon the achievement of certain target objectives associated with such corporate development projects. Additionally, Mr. Hunter will receive compensation equal to $250 per hour, along with reimbursement of reasonable pre-approved expenses, for services beyond the two corporate development projects noted above that are requested by the Company’s Chief Executive Officer. During the term of his service under the Consulting Agreement, any outstanding equity awards held by Mr. Hunter will continue to vest in accordance with their terms. The Consulting Agreement is terminable by the Company for Cause (as defined in the Consulting Agreement). In connection with the Consulting Agreement, Mr. Hunter has agreed to execute a general release agreement and to remain bound by the restrictive covenants in his existing confidentiality and noncompetition agreements with the Company, as modified by his Separation Agreement.

Appointment of Principal Financial Officer

On January 26, 2019, the Company’s board of directors appointed John M. Gay to serve as the Company’s Principal Financial Officer and Secretary effective January 31, 2019. Mr. Gay, age 42, will assume the role of Vice President, Finance in addition to continuing in the role of Corporate Controller. Mr. Gay has served as the Company’s Senior Director of Finance and Corporate Controller since May 2018, and previously held director-level positions, including Director of SEC Reporting, at Valassis Digital (formerly MaxPoint Interactive, Inc.), a digital marketing technology company, from May 2014 through April 2018, and Corporate Controller of Furiex Pharmaceuticals, Inc., a pharmaceutical development company, from June 2010 through May 2014. Prior to joining Furiex, Mr. Gay served as an Audit Senior Manager and in roles of increasing responsibility at Deloitte & Touche and Arthur Andersen, registered public accounting firms, from September 2000 through May 2010. He is a certified public accountant and holds Bachelor’s degrees in Economics and History and a Master of Accounting degree from the University of North Carolina at Chapel Hill.

There are no arrangements or understandings between Mr.Gay and any other persons to which he was appointed as an officer of the Company, he has no family relationships with any of the Company’s directors or executive officers, and he is not a party to, and he does not have any direct or indirect material interest in, any transaction requiring disclosure under Item 404(a) of RegulationS-K. In connection with his appointment to the role of Principal Financial Officer and Secretary, Mr. Gay is expected to enter into the Company’s standard indemnification agreement for its officers and directors.

In connection with his appointment to the position of Principal Financial Officer and Secretary, Mr. Gay received an increase in his annual salary of 25%, an increase in his annual bonus target of 10 percentage points, an incentive stock option award to purchase up to 35,000 shares of the Company’s common stock to the terms of the Company’s 2016 Incentive Award Plan, as amended, and an additional minimum bonus award under the Company’s Total Stockholder Return Plan, as amended.

Employment Agreement with Paula Brown Stafford

On January 29, 2019, the Company entered into an Employment Agreement (the “Employment Agreement”) with Paula Brown Stafford, in which Ms. Stafford has agreed to serve as the Company’s President and Chief Operating Officer. to the Employment Agreement, Ms. Stafford agrees to serve as the Company’s President and Chief Operating Officer for an initial term of one year, which term shall automatically extend for successive one year periods unless earlier terminated, receives an annual base salary of $450,000, is eligible to receive an annual performance-based bonus with a target bonus equal to 50% of her base salary, is eligible to participate in the Company’s incentive award plans and is entitled to the maximum amount of paid time-off under the Company’s policies. The Employment Agreement also provides Ms. Stafford with eligibility to participate in standard benefit plans as well as an executive life insurance plan and reimbursement of reasonable business expenses.

In the event of Ms. Stafford’s termination of employment by the Company without “cause” or by Ms. Stafford for “good reason,” not due to a “change in control,” each as defined in the Employment Agreement, then in addition to any accrued amounts and subject to Ms. Stafford timely delivering an effective release of claims in the Company’s favor and continued compliance with existing confidentiality and noncompetition agreements, Ms. Stafford will be entitled to receive (i)payment of an amount equal to 12months of her base salary, plus a prorated annual bonus, calculated based on 50% achievement of objectives, paid in installments over 12months in accordance with standard payroll practices, (ii) vesting of any of Ms. Stafford’s time-based options that would have vested during the 12 months following such separation and (iii) reimbursement of Ms. Stafford’s applicable COBRA premiums for up to 12months after such separation. In the event of Ms. Stafford’s termination of employment by the Company without “cause” or by Ms. Stafford for “good reason,” within six months of a “change in control,” each as defined in the Employment Agreement, then in addition to any accrued amounts and subject to Ms. Stafford timely delivering an effective release of claims in the Company’s favor and continued compliance with existing confidentiality and noncompetition agreements, Ms. Stafford will be entitled to receive (i)payment of an amount equal to 12months of her base salary, plus her annual bonus, calculated based on 50% achievement of objectives, paid in installments over 12months in accordance with standard payroll practices, (ii) vesting of all of Ms. Stafford’s outstanding unvested options and (iii) reimbursement of Ms. Stafford’s applicable COBRA premiums for up to 12months after such separation. Upon separation from service by Ms. Stafford other than for good reason or due to death or disability, or by the Company for cause, Ms. Stafford will not be entitled to any additional compensation beyond any accrued amounts.

Prior to Ms. Stafford and the Company entering into the Employment Agreement, Ms. Stafford was being compensated to the terms of her previous employment agreement, dated March 16, 2017, by and between Novan, Inc. and Ms. Stafford, as amended October 12, 2017 and March 14, 2018.

On January 30, 2019, the Company issued a press release announcing the appointment of Mr. Gay to the position of Principal Financial Officer and Corporate Secretary and certain business updates. The full text of this press release is furnished herewith as Exhibit 99.1 to this Current Report and incorporated herein by reference.

The information in this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section. Furthermore, the information in Item 7.01 of this report shall not be deemed incorporated by reference into the filings of the Company under the Securities Act of 1933, as amended.

EXHIBIT INDEX

Novan, Inc. Exhibit
EX-99.1 2 novan_businessupdatex01301.htm EXHIBIT 99.1 Exhibit Exhibit 99.1Novan Provides Business Update•End-of-Phase 2 meeting with FDA for molluscum granted and scheduled for early March•Active business development discussions ongoing around certain late-stage assets and broader dermatology platform•Dr. David Hebert joins Novan as Senior Director of Biometrics•John M. Gay,…
To view the full exhibit click here

About Novan, Inc. (NASDAQ:NOVN)

Novan, Inc. is a late-stage pharmaceutical company. The Company is engaged in the development and commercialization of therapies using its nitric oxide platform. The Company develops product candidates using its Nitricil technology, which enables the Company to engineer tunable new chemical entities (NCEs). The Company’s formulation science enables it to further tune the release of nitric oxide when applied to the skin by using the combinations of inactive ingredients. It is developing SB204 for the treatment of acne vulgaris in Phase III. The Company is developing its product candidate, SB206, for the treatment of external genital and perianal warts in Phase II. It is developing SB208, an investigational topical anti-fungal for the treatment of fungal infections of the skin and nails. It is developing SB204 for the treatment of inflammatory skin diseases. Its pipeline also includes SB414, a topical cream product candidate.